Mechanism-Based Enzyme Inactivation

From Reversible Binding to Progressive Enzyme Loss

Equilibrium inhibition changes an enzyme's activity while inhibitor is present. Mechanism-based inactivation adds a different process: the inhibitor first binds reversibly, then the bound complex proceeds to an inactive enzyme state. As a result, active enzyme can decline during exposure rather than merely being occupied temporarily. This distinction matters in PBPK models when a drug's unbound concentration at the enzyme site changes over time and its metabolic capacity depends on how much active enzyme remains.

The minimal scheme has three states. The active enzyme \(E\) and inhibitor \(I\) form a reversible complex \(EI\). That complex can proceed to inactive enzyme \(E_{\text{inact}}\). The inactivation step may represent a chemical transformation or another mechanism that makes the enzyme unavailable for catalysis; the simple model does not represent those molecular details separately.

Here, \(k_{\text{on}}\) is the association rate constant, \(k_{\text{off}}\) is the dissociation rate constant, and \(k_{\text{inact}}\) is the rate constant for inactivation of inhibitor-bound enzyme. In the scheme, \(k_{\text{inact}}\) has units of inverse time. It is not the overall inactivation rate at every inhibitor concentration: binding limits how much enzyme reaches the complex state.

Deriving the Saturable Inactivation Rate Law

Let \([I]\) denote the unbound inhibitor concentration at the enzyme site, and let \(E_{\text{act}}\) denote the amount of active enzyme, including its unbound and inhibitor-bound forms. To obtain a simple rate law, assume that \([I]\) is approximately constant during the interval considered, inhibitor binding and dissociation equilibrate rapidly relative to the decline in active enzyme, and the inactivation step is first order in \(EI\). Also assume that enzyme loss occurs only through this route: there is no enzyme synthesis, recovery, or competing loss in this model.

Under the rapid-equilibrium or steady-state approximation for the binding step, the amount of complex relative to free enzyme is determined by balancing its formation and removal. For the stated scheme, setting the net rate of change of \(EI\) to zero gives \(k_{\text{on}}[I][E]= (k_{\text{off}}+k_{\text{inact}})[EI]\). Therefore define the apparent inactivation constant \(K_I=(k_{\text{off}}+k_{\text{inact}})/k_{\text{on}}\). The fraction of active enzyme in the complex is then \([I]/(K_I+[I])\). Multiplying that fraction by the inactivation rate constant gives the first-order rate of loss of active enzyme:

The approximation for the complex fraction relies on the binding step being fast enough to track the active enzyme pool. If binding does not equilibrate rapidly, a model that explicitly tracks \(E\), \(EI\), and \(E_{\text{inact}}\) may be needed instead. In the simple rate law, \(k_{\text{obs}}\) is the observed first-order inactivation rate at the specified inhibitor concentration.

For the elementary scheme above, the steady-state derivation gives \(K_I=(k_{\text{off}}+k_{\text{inact}})/k_{\text{on}}\). Under rapid equilibrium with inactivation slow relative to dissociation, this can be close to the reversible dissociation constant \(k_{\text{off}}/k_{\text{on}}\). In applications, however, \(K_I\) is commonly treated as an apparent concentration parameter from the inactivation rate law. It should not automatically be interpreted as a binding affinity or equated with \(K_i\) from a reversible inhibition model.

Enzyme Loss During Constant Exposure

If \([I]\), \(k_{\text{inact}}\), and \(K_I\) remain constant, then \(k_{\text{obs}}\) is constant and the differential equation has an exponential solution. Let \(E_{\text{act}}(0)\) be active enzyme at the start of exposure. Separating variables and integrating from time zero to \(t\) gives:

Thus the fraction remaining depends on the accumulated inactivation rate over time, not just on the inhibitor concentration at the final observation. With changing inhibitor concentration, the same integration applies when the rate law responds instantaneously to the concentration: \(E_{\text{act}}(t)/E_{\text{act}}(0)=\exp[-\int_0^t k_{\text{obs}}(u)\,du]\). This extension assumes the model's binding approximation remains valid as concentration changes.

Changing Exposure and PBPK Interpretation

In a PBPK model, the relevant concentration is the unbound inhibitor concentration at the enzyme site, not automatically the plasma total concentration. If that site concentration changes, the inactivation rate changes with it. For piecewise-constant concentrations, calculate \(k_{\text{obs}}\) in each interval and add the interval-specific rate-time products. This is equivalent to integrating the rate over time.

If this enzyme contributes to a metabolic pathway, a simple model may scale that pathway's capacity in proportion to active enzyme. For example, if the pathway's baseline \(V_{\max}\) is \(12.0\ \text{mg/h}\), and its active enzyme fraction is 0.830, the corresponding capacity is \(12.0\times0.830=9.96\ \text{mg/h}\), provided substrate kinetics and the enzyme's catalytic activity per active amount are unchanged. Other pathways are not reduced by this calculation. The fraction should modify only the pathway represented by the inactivated enzyme.

Comparisons, Assumptions, and Failure Modes

Reversible equilibrium inhibition and mechanism-based inactivation represent different effects. A reversible model changes substrate metabolism according to inhibitor binding while the inhibitor is present; it does not, by itself, make the amount of active enzyme progressively decline. The inactivation model instead tracks that decline and can therefore retain an effect after the inhibitor concentration falls. Modeling this persistence requires retaining the active-enzyme state; the equilibrium inhibition factor alone cannot represent cumulative enzyme loss.

The saturable rate law also differs from assuming a single concentration-independent first-order inactivation rate. At low \([I]\), the linear approximation may be adequate if \([I]\ll K_I\); at concentrations near or above \(K_I\), it misses the saturation in \(k_{\text{obs}}\). Conversely, a full state model for \(E\) and \(EI\) is more mechanistic but needs binding-rate information and may be unnecessary when the rapid-binding approximation is justified.

The model is most interpretable when site concentration is known or represented appropriately, the inhibitor concentration is not substantially depleted by binding or reaction, and the inactivation pathway can be summarized by the stated scheme. It does not distinguish multiple binding modes, represent inhibitor metabolites, or include enzyme replacement. If concentration varies rapidly relative to binding, if the data show behavior inconsistent with a single saturable rate, or if enzyme activity changes for reasons other than the inhibitor, the simple rate law may not adequately describe the system. In such cases, inspect the assumptions before assigning a biological interpretation to its parameters.